"Gastrointestinal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
| Descriptor ID |
D005765
|
| MeSH Number(s) |
D27.505.954.483
|
| Concept/Terms |
Gastrointestinal Agents- Gastrointestinal Agents
- Agents, Gastrointestinal
- Gastrointestinal Drugs
- Drugs, Gastrointestinal
Gastric Agents- Gastric Agents
- Agents, Gastric
- Gastric Drugs
- Drugs, Gastric
|
Below are MeSH descriptors whose meaning is more general than "Gastrointestinal Agents".
Below are MeSH descriptors whose meaning is more specific than "Gastrointestinal Agents".
This graph shows the total number of publications written about "Gastrointestinal Agents" by people in this website by year, and whether "Gastrointestinal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 36 | 16 | 52 |
| 2018 | 35 | 16 | 51 |
| 2019 | 17 | 3 | 20 |
| 2020 | 4 | 2 | 6 |
| 2021 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Gastrointestinal Agents" by people in Profiles.
-
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. J Crohns Colitis. 2021 Nov 08; 15(11):1877-1884.
-
Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis. 2021 Jul 05; 15(7):1211-1221.
-
Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy. J Crohns Colitis. 2021 Jul 05; 15(7):1244-1245.
-
COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States. Gastroenterology. 2021 10; 161(4):1336-1339.e3.
-
Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease. Gastroenterology. 2021 10; 161(4):1340-1343.e2.
-
Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD. Nat Rev Gastroenterol Hepatol. 2021 05; 18(5):286.
-
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021 10; 70(10):1884-1893.
-
Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [PIMS-TS] in a Patient Receiving Infliximab Therapy for Inflammatory Bowel Disease. J Crohns Colitis. 2021 Apr 06; 15(4):687-691.
-
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021 05; 70(5):865-875.
-
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Lancet Gastroenterol Hepatol. 2021 02; 6(2):88-89.